HS1 - L24 Pharmacology and Functional Organisation of the Sympathetic Nervous System

Functional Organisation of the Nervous System

  • The nervous system is divided into two primary structural components:
    • Central Nervous System (CNS): Consists of the brain and the spinal cord.
    • Peripheral Nervous System (PNS): Consists of the cranial and spinal nerves.
  • The nervous system is further categorized into functional divisions:
    • Motor Division (Efferent): Transmits signals from the CNS to effector organs.
    • Sensory Division (Afferent): Transmits signals from sensory receptors to the CNS.
  • The Motor Division contains two main systems:
    • Somatic Nervous System: Responsible for voluntary control of skeletal muscles.
    • Autonomic Nervous System (ANS): Responsible for involuntary control of internal organs and glands.
  • The Autonomic Nervous System is subdivided into:
    • Sympathetic Nervous System
    • Parasympathetic Nervous System
    • Enteric Nervous System: Manages the gastrointestinal tract and can operate independently of the CNS.

Anatomical Projections and Ganglia

  • Sympathetic Nervous System Projections:
    • Projections originate from the Cervical, Thoracic, and Lumbar regions of the spinal cord.
    • Major ganglia involved include the Superior cervical ganglion, Stellate ganglion, Paravertebral chain, Celiac ganglion, Superior mesenteric ganglion, and Inferior mesenteric ganglion.
    • The Splanchnic nerve delivers signals to various abdominal organs.
    • The Adrenal medulla receives direct sympathetic innervation.
  • Parasympathetic Nervous System Projections:
    • Projections originate from the Midbrain, Pons, Medulla, and the Sacral region of the spinal cord.
    • Key cranial nerves for the parasympathetic system include:
      • Oculomotor nerve (III): Projects to the eye.
      • Facial nerve (VII) and Glossopharyngeal nerve (IX): Project to the lacrimal and salivary glands.
      • Vagus nerve (X): Provides extensive innervation to the lungs, heart, liver, stomach, pancreas, small intestine, and large intestine/rectum.
    • The Sacral region provides innervation to the bladder and reproductive organs.

Physiological Effects of Autonomic Stimulation

  • Eye (Iris):
    • Sympathetic: Pupil dilation.
    • Parasympathetic: Pupil constriction.
  • Salivary Glands:
    • Sympathetic: Reduced production of saliva.
    • Parasympathetic: Increased production of saliva.
  • Oral and Nasal Mucosa:
    • Sympathetic: Reduced mucus production.
    • Parasympathetic: Increased mucus production.
  • Heart:
    • Sympathetic: Increased heart rate and increased force of contraction.
    • Parasympathetic: Decreased heart rate and decreased force of contraction.
  • Lungs:
    • Sympathetic: Relaxation of bronchial muscle (bronchodilation).
    • Parasympathetic: Contraction of bronchial muscle (bronchoconstriction).
  • Stomach:
    • Sympathetic: Reduced peristalsis.
    • Parasympathetic: Increased motility and secretion of gastric juice.
  • Small Intestine:
    • Sympathetic: Reduced motility.
    • Parasympathetic: Increased digestion activities.
  • Large Intestine:
    • Sympathetic: Reduced motility.
    • Parasympathetic: Increased secretions and motility.
  • Liver:
    • Sympathetic: Increased conversion of glycogen to glucose.
  • Kidney:
    • Sympathetic: Decreased urine secretion.
    • Parasympathetic: Increased urine secretion.
  • Adrenal Medulla:
    • Sympathetic: Secretion of norepinephrine and epinephrine.
  • Bladder:
    • Sympathetic: The bladder wall is relaxed and the sphincter is closed.
    • Parasympathetic: The bladder wall is contracted and the sphincter is relaxed.

Chemical Transmission and Synaptic Organisation

  • Parasympathetic Pathway: Signals travel from the CNS to a ganglion via Acetylcholine (AChACh) acting on Nicotinic (nn) receptors. From the ganglion, the signal moves to the effector organ via AChACh acting on Muscarinic (mm) receptors.
  • Sympathetic Pathway (Standard): Signals travel from the CNS to a ganglion via AChACh acting on Nicotinic receptors. From the ganglion, the signal moves to the effector organ via Noradrenaline (NAdNAd/Norepinephrine).
  • Sympathetic Pathway (Adrenal): Signals travel from the CNS via AChACh acting on Nicotinic receptors in the Adrenal medulla, which then releases Adrenaline (AdAd/Epinephrine) and some NAdNAd directly into the bloodstream.
  • Cholinergic Transmission Specifics:
    • The synapse between all preganglionic sympathetic and parasympathetic neurons involves the release of AChACh onto neuronal nicotinic receptors (nAChRs).
    • Neuronal nAChRs consist of α2−7\alpha 2-7 subunits, most commonly configured as (α3)2(β4)3(α3)_2(β4)_3.
    • The nAChR is an ion channel that allows the influx of Na+Na^+ when two molecules of AChACh bind to the extracellular domain.
  • Hexamethonium:
    • This is a selective antagonist for the neuronal sub-type of nicotinic receptors.
    • It is not a competitive antagonist.
    • It effectively blocks all effects resulting from autonomic stimulation.

Adrenoceptors: Classification and Function

  • Adrenoceptors are the key receptors responding to noradrenaline released from sympathetic terminals and circulating noradrenaline.
  • All adrenoceptors are G-protein coupled receptors (GPCRs) containing seven transmembrane domains, an extracellular ligand-binding domain, and an intracellular G-protein coupling domain.
  • Sub-type Specificity:
    • α1\alpha_1: Responsible for smooth muscle contraction (e.g., vasoconstriction).
    • α2\alpha_2: Involved in vasoconstriction and acts as a pre-synaptic receptor for feedback inhibition.
    • β1\beta_1: Increases heart rate and contractility.
    • β2\beta_2: Responsible for smooth muscle relaxation (e.g., bronchodilation and vasodilation).
    • β3\beta_3: Causes relaxation of the bladder smooth muscle and stimulates lipolysis.

G-Protein Signaling Mechanism

  • The Signaling Cycle:
    • In the inactive state, the receptor is associated with a G protein complex (α,β,γ\alpha, \beta, \gamma subunits) bound to GDPGDP.
    • Upon ligand (noradrenaline) binding, GTPGTP replaces GDPGDP on the α\alpha subunit.
    • The activated G protein interacts with a target protein in the plasma membrane (e.g., an enzyme or ion channel) to produce a cellular effect.
  • α1\alpha_1 Adrenoceptor Coupling:
    • The α1\alpha_1 receptor is coupled to the GqG_q protein.
    • The GqG_q protein activates Phospholipase C-β\beta (PLCPLC).
    • PLCPLC converts membrane phosphoinositides into Inositol trisphosphate (IP3IP_3) and Diacylglycerol (DAGDAG).
    • IP3IP_3 binds to IP3IP_3 receptors on the endoplasmic reticulum, facilitating the release of intracellular Calcium (Ca2+Ca^{2+}).
    • The resulting increase in Ca2+Ca^{2+} concentration produces the physiological effect (e.g., contraction).

Pharmacological Applications of Sympathetic Agents

  • α\alpha-Receptor Agonists:
    • Vasoconstrictors with local anaesthetics: Adrenaline and Noradrenaline (primarily acting on α1\alpha_1).
    • Nasal Decongestants: Phenylephrine (primarily α1\alpha_1).
    • Hypertension Treatment: Clonidine, which acts on central α2\alpha_2 receptors.
  • β\beta-Receptor Agonists:
    • Cardiogenic Shock: Adrenaline and Dobutamine (acting on β1\beta_1).
    • Anaphylactic Shock: Adrenaline (mixed α/β\alpha/\beta agonist action).
    • Asthma: Salbutamol (selective β2\beta_2 agonist); also used to delay premature labour.
  • α\alpha-Antagonists:
    • Hypertension: Doxazosin (selective α1\alpha_1 antagonist).
    • Benign Prostatic Hyperplasia: Tamsulosin (selective α1\alpha_1 antagonist).
  • β\beta-Antagonists (Beta-blockers):
    • Examples include Propranolol (non-selective β1/β2\beta_1/\beta_2) and Metoprolol (selective β1\beta_1).
    • Indications: Angina, cardiac arrhythmias, hypertension, anxiety states, and chronic heart failure.
    • Glaucoma: Timolol is used locally.

Noradrenaline Synthesis and Metabolism

  • Synthesis Pathway:
    1. Tyrosine is converted into Dihydroxyphenylalanine (DOPA).
    2. DOPA is converted into Dopamine.
    3. Dopamine is transported into storage vesicles by the Vesicular Monoamine Transporter (VMAT).
    4. Inside the vesicle, dopamine is converted into Noradrenaline (NAd).
  • Degradation Enzymes:
    • Monoamine Oxidase (MAO): Breaks down catecholamines within the nerve terminal (mitochondria).
    • Catechol-O-methyltransferase (COMT): Breaks down catecholamines in muscle cells or other effector cell types.

Termination of Noradrenaline Action: Uptake 1

  • Mechanism of Uptake 1:
    • This is the primary mechanism for terminating the actions of NAdNAd in the synapse using the Norepinephrine Transporter (NET).
    • It is a secondary active transporter that cotransports Na+Na^+, Cl−Cl^-, and the catecholamine.
    • Properties: High affinity for noradrenaline but a low maximal rate of uptake. It is relatively selective (NAd>Ad>isoprenalineNAd > Ad > isoprenaline).
  • Inhibitors of NET:
    • Inhibitors include cocaine, tricyclic antidepressants (such as desipramine), and phenoxybenzamine.
    • NET is closely related to transporters for dopamine (DAT) and serotonin (SERT).
    • Inhibitory Effects:
      • Desipramine: A tricyclic antidepressant used primarily in the CNS. Adverse effects include tachycardia and dysrhythmia.
      • Cocaine: Acts as a local anaesthetic but also causes euphoria and excitement (CNS) and tachycardia/increased blood pressure (Peripheral).

Mono-amine Oxidase Inhibitors (MAOIs)

  • Most MAOIs block the enzyme irreversibly.
  • They are used clinically as antidepressants to increase brain and peripheral levels of noradrenaline, dopamine, and 5-HT5\text{-HT}.
  • Adverse Effects: Postural hypotension, weight gain, restlessness, and insomnia.
  • Cheese Reaction: A hypertensive episode characterized by flushing that occurs when a patient on MAOIs consumes tyramine-containing food (e.g., cheese).
  • Examples: Phenelzine, tranylcypromine, and iproniazid are irreversible inhibitors; Moclobemide is a reversible, competitive inhibitor.

Indirectly Acting Sympathetic Amines

  • Examples include Amfetamine, ephedrine, and tyramine.
  • These compounds are structurally related to noradrenaline and utilize the NET for transport into the nerve terminal and vesicles.
  • Action Mechanism: They displace endogenous noradrenaline from vesicles. The noradrenaline then leaks out into the synapse via the NET.
  • They produce similar effects on dopamine and 5-HT5\text{-HT} in the CNS.
  • Physiological Effects: Mimic noradrenaline's long-lasting effects, including bronchodilatation, vasoconstriction, positive inotropy, and raised blood pressure.
  • Their CNS effects contribute to their potential as substances of abuse.

Physiological Dimensions of Sympathetic Nerves

  • Postganglionic sympathetic nerves vary in length from 1 cm1\,cm up to 1 m1\,m.
  • The axon diameter is roughly 30 μm30\,\mu m.
  • Varicosities on the nerve terminal have the following approximate dimensions:
    • Varicosity diameter: ≈1 μm\approx 1\,\mu m.
    • Individual vesicle diameter: ≈0.1 μm\approx 0.1\,\mu m.
    • Spacing between varicosities: ≈2 μm\approx 2\,\mu m.
    • Synaptic cleft width: 1.5 μm to 2 μm1.5\,\mu m \text{ to } 2\,\mu m.